Unique ID issued by UMIN | UMIN000045499 |
---|---|
Receipt number | R000051490 |
Scientific Title | Follow up study of Phase II clinical trial of OCV-501 |
Date of disclosure of the study information | 2021/09/16 |
Last modified on | 2022/08/05 16:14:36 |
Follow up study of Phase II clinical trial of OCV-501
NMC-OCV501-AML
Follow up study of Phase II clinical trial of OCV-501
NMC-OCV501-AML
Japan |
acute myeloid leukemia
Hematology and clinical oncology |
Malignancy
NO
This study aims to investigate a long-term follow-up of patients 60 years or older with acute myeloid leukemia (AML) who participated in the phase 2 randomized trial to evaluate the efficacy and safety of OCV-501 monotherapy or placebo (#NCT01961882).
Efficacy
5-year disease free survival; OCV-501 group vs. placebo group
5-year overall survival; OCV-501 group vs. placebo group
Specific immunological responses to WT-1 and prognosis
Level of WT1 mRNA and prognosis
Observational
Not applicable |
Not applicable |
Male and Female
Registered cases in OCV-501 Phase II study
1) Cases showing a manifestation of non-participation in this study
2) Cases who the principal investigator deems inappropriate as a research subject
80
1st name | Tomoki |
Middle name | |
Last name | Naoe |
National Hospital Organization Nagoya Medical Center
Honorary Director
460-0001
4-1-1 Sannomaru, Naka-ku, Nagoya, Aichi, Japan
052-951-1111
naoe.tomoki.wx@mail.hosp.go.jp
1st name | Tomoki |
Middle name | |
Last name | Naoe |
National Hospital Organization Nagoya Medical Center
Honorary Director
460-0001
4-1-1 Sannomaru, Naka-ku, Nagoya, Aichi, Japan
052-951-1111
naoe.tomoki.wx@mail.hosp.go.jp
National Hospital Organization Nagoya Medical Center IRB
International Institute of Cancer Immunology, Inc.
Profit organization
National Hospital Organization Nagoya Medical Center IRB
4-1-1 Sannomaru, Naka-ku, Nagoya 460-0001 JAPAN, Aichi
052-951-1111
311-rec@mail.hosp.go.jp
NO
2021 | Year | 09 | Month | 16 | Day |
Unpublished
133
Completed
2021 | Year | 09 | Month | 07 | Day |
2021 | Year | 09 | Month | 15 | Day |
2021 | Year | 09 | Month | 16 | Day |
2022 | Year | 03 | Month | 31 | Day |
5-year disease free survival; OCV-501 group vs. placebo group
5-year overall survival; OCV-501 group vs. placebo group
Specific immunological responses to WT-1 and prognosis
Level of WT1 mRNA and prognosis
2021 | Year | 09 | Month | 16 | Day |
2022 | Year | 08 | Month | 05 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051490
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |